Clinical Trial Update: Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating vildagliptin (Galvus) as add-on to insulin in newly diagnosed Type 1 diabetes mellitus, with the trial status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Galvus (vildagliptin)
• Insulin (insulin)

Snippet

Sponsor: Federal University of São Paulo | Conditions: Type 1 Diabetes, Insulin Dependent Diabetes | Phase 3 | Status: UNKNOWN